Navigation Links
ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society
Date:5/18/2011

REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that the results from its Phase 2 clinical studies related to two product candidates, ARX-01 Sufentanil NanoTab(R) PCA System, which is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia and ARX-03 to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office, will be featured in poster presentations at the upcoming  American Pain Society Annual Meeting to be held in Austin, TX, on May 18th-21st, 2011.  Commenting on the poster presentations, Pamela Palmer, MD, PhD, AcelRx co-founder and Chief Medical Officer said, "We are delighted that these data are being presented at this prestigious meeting by investigators involved in the studies.  In particular, the combined data from ARX-01 Phase 2 studies highlight advantages of our post-operative pain management approach over existing methods that we hope to confirm in our Phase 3 studies."

Lead investigator, Harold Minkowitz, MD of the Memorial Hermann Memorial City Medical Center in Houston, TX will present analyses of the combined results from two randomized, placebo-controlled Phase 2 studies and one Phase 2 open-label system functionality study evaluating the safety and efficacy of the ARX-01 sublingual Sufentanil NanoTab(R) PCA System. ARX-01 is a non-invasive, sublingual alternative to intravenous patient-controlled analgesia (IV PCA). The results from the 212 patients included in these three studies indicate that ARX-01 was effective in treating both major orthopedic and major abdominal post-operative pain with minimal adverse effects.

Also presented will be results from a randomized, placebo-controlled Phase 2 study to evaluate the safety and effectiveness of ARX-03, a novel sublingual combination of sufentanil and triazolam that offers mild sedation, anxiolysis and analges
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... FORT MYERS, Fla. , Jan. 23, 2015  Today ... approval of Novartis, Bexsero® for the prevention of ... to 25. Bexsero and Pfizer,s vaccine Trumenba®, which received ... in helping prevent this devastating disease. ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... , , ROCKVILLE, Md., ... tissue proteomic analysis, today announced Mayo Clinic has ... patent for use in diagnosis of systemic amyloidosis ... enables solubilization of proteins for mass spectrometric analysis ...
... , NEW ... a new market research report is available ... Russian, Indian and Chinese Markets for Endoscopic ... http://www.reportlinker.com/p0164164/Brazil-Russian-Indian-and-Chinese-Markets-for-Endoscopic-Devices-2009-(4-Countries ).html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , The ...
Cached Medicine Technology:Liquid Tissue(R) Patent Licensed for Amyloidosis Proteomic Assay 2Reportlinker Adds Brazil, Russian, Indian and Chinese Markets for Endoscopic Devices 2009 (4 Countries) 2
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... , , , , NEW ... make a New Year,s resolution this year. Losing weight and developing healthy ... common goals. Historically, 30% of resolutions are broken in the first week ... committed to adopting healthier habits in 2010, The Biggest Loser Resort at ...
... , IDAHO FALLS, Idaho, Dec. 31 International Isotopes ... its license application to the U. S. Nuclear Regulatory ... extraction processing facility. , Steve T. Laflin, President and ... another significant accomplishment for the Company and is the ...
... , ... a mom shows that Narconon brought another family together for the holidays , ... (PRWEB) December 31, 2009 -- Celebrating the ... received another life changing success story evoking the true spirit of the holidays. "Before ...
... habit? Just in time for New Year,s resolutions, a ... to increase one,s risk for age-related macular degeneration (AMD), the ... The American Journal of Ophthalmology publishes the ... that it,s never too late to quit smoking," said lead ...
... the Streptococcus pneumoniae in samples that can ... predict risk of severe disease in H1N1 pandemic influenza. ... with higher morbidity and mortality than in other countries ... (CII) at the Mailman School of Public Health of ...
... ... Iceland, December 30 deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced ... stating that for 30 consecutive,business days the market value of the ... the minimum level required for continued,listing on The Nasdaq Global Market ...
Cached Medicine News:Health News:Healthy, Delicious Recipes and Tips From the Biggest Loser Resort Help Celebrate a New Year and a New You 2Health News:Healthy, Delicious Recipes and Tips From the Biggest Loser Resort Help Celebrate a New Year and a New You 3Health News:International Isotopes Inc. Announces Submission of the License Application for Their Uranium De-conversion and Fluorine Extraction Processing Facility 2Health News:International Isotopes Inc. Announces Submission of the License Application for Their Uranium De-conversion and Fluorine Extraction Processing Facility 3Health News:Mother and Son Spend Holidays Free of Drug Addiction 2Health News:It's never too late to quit smoking and save your vision 2Health News:Severity of H1N1 influenza linked to presence of Streptococcus pneumoniae 2Health News:deCODE Receives Nasdaq Deficiency Notice 2Health News:deCODE Receives Nasdaq Deficiency Notice 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: